Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. - Wikidata - awgldk - TriplyDB

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

http://www.wikidata.org/entity/Q34535641

about

Viral Infections and Obesity.Gut-Brain Cross-Talk in Metabolic Control.Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity.Rare Variant Analysis of Human and Rodent Obesity Genes in Individuals with Severe Childhood Obesity.A Macrocyclic Agouti-Related Protein/[Nle4,DPhe7]α-Melanocyte Stimulating Hormone Chimeric Scaffold Produces Subnanomolar Melanocortin Receptor Ligands.From Bioinactive ACTH to ACTH Antagonist: The Clinical Perspective.Suppressed sympathetic outflow to skeletal muscle, muscle thermogenesis, and activity energy expenditure with calorie restriction.Melanocortin-4 Receptor Gene Mutations in a Group of Turkish Obese Children and Adolescents.Genetics of obesity: can an old dog teach us new tricks?Role of the brain melanocortins in blood pressure regulation.Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.Medication use for the treatment of diabetes in obese individuals.Interactome of Obesity: Obesidome : Genetic Obesity, Stress Induced Obesity, Pathogenic Obesity Interaction.Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice Gene-nutrient interactions and susceptibility to human obesity.Estimated prevalence of potentially damaging variants in the leptin gene.Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.Molecular Therapy of Melanocortin-4-Receptor Obesity by an Autoregulatory BDNF Vector.Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity.On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations.Cannabis in fat: high hopes to treat obesity.The current state of GPCR-based drug discovery to treat metabolic disease.Genetic and Syndromic Causes of Obesity and its Management.Molecular and functional genetics of the proopiomelanocortin gene, food intake regulation and obesity.Obesity Triggers: Sequencing the Genome Versus Sequencing the Environment.Toward Precision Approaches for the Prevention and Treatment of Obesity.Patient-Centered Reverse Translation.Early-Onset Obesity: Unrecognized First Evidence for GNAS Mutations and Methylation Changes.Neuroendocrinology: New hormone treatment for obesity caused by POMC-deficiency.Binding, Thermodynamics, and Selectivity of a Non-peptide Antagonist to the Melanocortin-4 Receptor.CoDE-seq, an augmented whole-exome sequencing, enables the accurate detection of CNVs and mutations in Mendelian obesity and intellectual disability.Centrally Acting Agents for Obesity: Past, Present, and Future

P2860

Q30235298-EC291987-DA49-45D2-AEDE-73FCBB61BE2C Q30235568-788D148E-E4D2-4EC9-83C5-65094DFEB105 Q33830475-3366D47A-86BA-437E-BD32-6D041B0EE017 Q33854345-B6FB736C-CB82-4E06-B5F7-950561F1A915 Q36237694-0EB4CE45-1A93-4574-B368-F9AB43C82C52 Q37629815-6ED0EEE9-E635-477E-A78D-713FA3BB0B01 Q38938629-B9D4C4B5-3F04-465A-B41F-DC115D891323 Q38952083-DFEF8C0E-BCDF-4BD0-981A-E1280121FDB3 Q39053286-7DE70FE9-8904-4FB8-BB8F-663AE26A5ECA Q39169242-5A92567B-1B69-4AD6-978F-464814FCD27E Q39211934-B7BA8C43-0856-4C39-8B43-C1FAEA14AF88 Q39304674-CC374FD3-0CAB-416F-BB28-ED962DC5F213 Q41991835-AF88E885-6C96-4AC2-800A-8FDF81415F94 Q42377845-E2288BB0-434A-4381-BE2C-603C424C8AEA Q42377882-6329BBC6-B84B-42EC-8449-7A7BE949669F Q44777143-A8773938-C3EB-4E22-8441-2B390B286702 Q45035792-266EFF10-0275-4FE5-AD36-A6A03DC8F398 Q46036092-9004CD93-5FB6-4CEC-93B7-BBAD1FE1B08A Q47103932-1674CF6E-E5F2-4222-959B-7E348F7A394B Q47177885-284AA164-A5BA-422A-B761-469B9C9F720D Q47607244-099AD6A8-92CF-4414-86B7-AEB339913E00 Q47673250-5A4C9A4F-D38E-4406-8315-E5261CA806FB Q47696468-DC6CD3A6-A799-414F-B5C6-49D4D6E6866A Q47949193-A4B3D49C-BCB5-4DB0-AF2D-5BDC6639A560 Q47995304-717CF2B5-C82D-457A-AA9C-B40A9F01E294 Q48097740-023F7771-FCC1-4923-BC74-5962E4CA20D0 Q49774579-0E4E3EA9-0FAE-4606-BEC8-D66F24CD96C9 Q50054779-2E3419A2-EC26-4C02-8936-F620E7E0127D Q51029814-E1DA2D5A-8A6A-486D-8CB4-3581DEE54AEF Q53760093-CEB02264-5DA7-41C8-A6AB-897D5DA36D38 Q55092101-C4329E7C-E09B-47EB-9F9C-022544D2D23A Q55516130-03AD54FA-E00F-4954-A8C1-9DA8E705A503 Q57177981-B8B749BE-EAFA-4195-8F19-8453C7B0A1C2

P2860

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

http://www.wikidata.org/entity/Q34535641

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@ast

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@en

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@nl

type

label

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@ast

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@en

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@nl

prefLabel

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@ast

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@en

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@nl

P1433

Q34535641-5CD93AF7-2A80-4730-A878-02FD4342F1DE

P1476

Q34535641-41E28484-B5A5-4148-AD73-5AA9C192B877

P2093

Q34535641-0498CE20-AA06-4270-9C6F-A0559C5FAB97

Q34535641-2E18F049-8ED6-4985-8F04-E69E31E97C5D

Q34535641-34F05995-70DF-41AF-86F5-83FCF75D7659

Q34535641-5C7C230D-788B-4D07-82CA-62FC967E6603

Q34535641-74C13EDF-4967-4D10-B4D1-F57462D7B12B

Q34535641-C11915D4-7188-468B-B1B2-04B8B733F393

Q34535641-DF75A3E2-426B-4E3C-B04F-C60424530083

Q34535641-FE0C7DFA-4813-42C6-91F5-11CA03BFDF81

P304

Q34535641-0E0C3EFF-B6EC-4B0F-B471-C43A53B0439C

P31

Q34535641-43685D5D-1C1C-42C4-BF30-488B35456DB5

P356

Q34535641-08A01F71-8245-4548-8A78-90ACE6D0378E

P407

Q34535641-FDD18A69-E223-4B96-8157-333DDCDE90ED

P433

Q34535641-EDDB88A5-365D-4591-8A62-25C1D19002C6

P478

Q34535641-CA69E7D4-92F3-4846-8678-79D394D968D6

P50

Q34535641-15E750A2-7B2A-4605-8BB1-90BF748DE527

Q34535641-B2D3F9ED-4AFC-4B5B-8579-19AEDB97F12F

Q34535641-EE4AFD8F-62F3-43E7-8D16-91EC00F12CDE

P577

Q34535641-24F1DA34-1F2A-4EFA-AD21-FF4ABD8FBD99

P698

Q34535641-D155428F-7F20-4D80-91C1-99B0E54438AE

P356

P1433

The New England Journal of Medicine

P1476

Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.

@en

P2093

Annette Grüters

http://www.w3.org/2001/XMLSchema#string

Heiko Krude

http://www.w3.org/2001/XMLSchema#string

Keith Gottesdiener

http://www.w3.org/2001/XMLSchema#string

Knut Mai

http://www.w3.org/2001/XMLSchema#string

Lea L Martini

http://www.w3.org/2001/XMLSchema#string

Oliver Blankenstein

http://www.w3.org/2001/XMLSchema#string

Peter Kühnen

http://www.w3.org/2001/XMLSchema#string

Ulrike Blume-Peytavi

http://www.w3.org/2001/XMLSchema#string

P304

240-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1512693

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Susanna Wiegand

Ulrike Blume-Peytavi

Karine Clément

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27468060

http://www.w3.org/2001/XMLSchema#string